Lineage Cell Therapeutics, Inc.
LCTX
$0.4817
-$0.0183-3.66%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 31.46% | 57.33% | -10.15% | -49.63% | 24.85% |
| Total Depreciation and Amortization | -13.71% | -19.89% | -16.47% | 2.34% | 1.16% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -7.81% | -59.82% | -18.12% | 314.61% | -126.19% |
| Change in Net Operating Assets | -145.88% | -2,570.50% | 64.28% | 85.34% | 57.02% |
| Cash from Operations | -5.43% | -14.89% | 17.42% | 48.56% | 27.51% |
| Capital Expenditure | -301.10% | 19.42% | 80.47% | 79.79% | -668.75% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -69.49% | 76.91% | -145.03% | -- | 292.13% |
| Cash from Investing | -72.95% | 83.22% | -145.89% | -100.25% | 290.94% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -7.69% | -8.33% | 12.50% | 0.00% | -44.44% |
| Issuance of Common Stock | -- | -98.82% | -97.94% | 27,682.35% | -- |
| Repurchase of Common Stock | 100.00% | -- | -- | 37.84% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -129.15% | 100.00% | 99.43% | -- | 1,909.09% |
| Cash from Financing | 167,284.62% | -100.37% | -98.13% | 1,402,000.00% | -110.66% |
| Foreign Exchange rate Adjustments | -91.13% | 111.18% | 4.35% | 30.00% | 461.54% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 352.10% | 23.86% | -175.71% | 99.02% | 129.88% |
